Leukemia patients who received infusions of their own T cells, after the cells had been genetically engineered to fight the patients' cancerous tumors, reacted to the therapy in a positive way, staying in full remission for over two years. The new therapy was developed by a group of scientists...
An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine. The study will appear in the...
Clinical research has shown that recurrence of Mantle Cell Lymphoma, a variant of malignant lymphoma, can be reduced by almost 50% in patients who receive maintenance treatment with the antibody rituximab. These results are presented by Dr Hanneke Kluin-Nelemans at the 16th Congress of the...
Experimental drug Brentuximab Vedotin (SGN-35) achieved tumor volume reductions in 94% of Relapsed or Refractory Hodgkin Lymphoma patients while 34% of them achieved complete remission, Seattle Genetics reported after completing a Pivotal Clinical Trial. The company expects to submit the...
A new computer modeling programme has been devised to help predict the likelihood of complete remission or early death in patients aged 60 years or older undergoing intensive chemotherapy for acute myeloid leukaemia (AML). The findings are reported in an Article Online First and in an upcoming...
Light chain amyloidosis, a deadly protein misfolding disease, is caused by multiple mutations in cells that are intended to protect the body. Instead, the mutations send misfolded bundles of proteins through the bloodstream, potentially destroying the heart, kidneys, liver or other organs. Mayo...